Why is friedewald calculation generally performed using a fasting lipid sample, and when does this calculation become unreliable
Reading File
Searching the Web
Friedewald equation fasting sample unreliable triglycerides 400 mg/dL guidelines
Searching PubMed
Friedewald equation fasting triglycerides
Finding Sources
Reading File
The Friedewald calculation estimates LDL cholesterol:
LDL-C = Total cholesterol - HDL-C - (triglycerides/5) in mg/dL
(or triglycerides/2.175 in mmol/L).
(or triglycerides/2.175 in mmol/L).
It is traditionally performed on a fasting sample because the equation assumes:
- Almost all plasma triglyceride is contained in VLDL.
- VLDL has a relatively constant triglyceride:cholesterol ratio, approximated by TG/5.
After a meal, triglyceride-rich chylomicrons enter the circulation. Their triglyceride:cholesterol ratio differs substantially from VLDL, so TG/5 overestimates VLDL cholesterol and usually makes calculated LDL-C falsely low. Fasting reduces this chylomicron effect. Henry's Clinical Diagnosis and Management by Laboratory Methods, pp. 297-298.
It becomes unreliable when:
- Triglycerides are >400 mg/dL (4.52 mmol/L): do not report Friedewald LDL-C. The VLDL TG:cholesterol ratio is no longer adequately represented by a fixed divisor of 5.
- Triglycerides are 200-399 mg/dL: error becomes progressively more important, commonly underestimating LDL-C.
- Nonfasting samples with substantial chylomicrons: especially if postprandial TG is high.
- Type III dysbetalipoproteinemia / beta-VLDL: beta-VLDL is relatively cholesterol-rich, violating the formula’s assumptions and potentially overestimating LDL-C.
- Very low LDL-C, such as in patients on potent lipid-lowering therapy: relative inaccuracy rises.
For high TG or situations needing precise LDL-C, consider a direct LDL-C measurement, non-HDL-C, apoB, or a newer validated LDL-C equation such as Martin-Hopkins or Sampson. The laboratory medicine review similarly describes the nonfasting chylomicron issue and the conventional >400 mg/dL cutoff.
Find recent guidelines on fasting versus nonfasting lipid testing
Reading File
Reading File
Searching the Web
2024 2025 guideline fasting nonfasting lipid testing guideline statement
Searching the Web
guideline nonfasting lipid testing fasting triglycerides 2023 consensus
Searching PubMed
nonfasting lipid testing guideline
Searching PubMed
nonfasting lipid profile fasting systematic review
Finding Sources
Reading File
Reading Article
PMID: 39225455
Reading Article
PMID: 38937752
Reading Article
PMID: 35378262
Reading Web Page
https://www.nice.org.uk/guidance/ng238/chapter/Recommendatio…
Searching the Web
site:acc.org 2026 lipid profile testing fasting nonfasting triglycerides 400 guideline
Reading Web Page
https://tools.acc.org/ldl
Current guidance: fasting is usually not required
Recent guidance broadly supports a nonfasting lipid panel for routine cardiovascular risk assessment and lipid monitoring. Total cholesterol, HDL-C, non-HDL-C, apoB, and Lp(a) are generally suitable in the nonfasting state. Post-meal triglyceride increases are usually modest for most people.
- The 2024 ADLM lipid-testing guidance states that fasting is not routinely required, while recommending modern LDL-C equations where possible.
- Current NICE lipid-modification guidance defines a full lipid profile without mandating fasting.
- The current ACC Lipid Manager guidance states that either fasting or nonfasting panels can be used in most adults to estimate ASCVD risk and document baseline LDL-C.
- Major-society acceptance of routine nonfasting assessment is also summarized in Tietz Textbook of Laboratory Medicine, which notes that nonfasting samples are acceptable for routine lipid assessment and that postprandial triglyceride rises are usually clinically insignificant. Tietz Textbook of Laboratory Medicine, 7th ed., p. 1177.
When a fasting lipid panel is preferred
Obtain or repeat a fasting panel when the result will affect interpretation or management of triglycerides or calculated LDL-C:
| Clinical situation | Why fasting helps |
|---|---|
| Nonfasting TG >400 mg/dL (4.5 mmol/L) | Repeat fasting panel to establish TG and LDL-C more reliably. This is the ACC threshold. |
| Nonfasting TG ≥500 mg/dL (5.6 mmol/L) | Needed to assess possible severe hypertriglyceridemia and pancreatitis risk. |
| Suspected or known hypertriglyceridemia | Diagnosis and serial assessment of persistent hypertriglyceridemia are conventionally based on fasting TG. |
| Before triglyceride-directed drug treatment | ACC guidance advises fasting measurements, commonly two measurements at least 2 weeks apart, before initiating TG risk-based nonstatin therapy. |
| Suspected genetic dyslipidemia or markedly abnormal lipid profile | Baseline characterization may be clearer fasting. |
| Evaluation for metabolic syndrome | The diagnostic criterion uses fasting glucose and historically fasting TG assessment is favored. |
| When calculated LDL-C is near a treatment threshold and TG is elevated | Food intake and high TG can distort calculated LDL-C, especially with the Friedewald equation. Consider non-HDL-C, apoB, or a modern LDL-C equation. |
For very high triglycerides, NICE advises specialist action rather than simply repeating routine testing: urgent specialist review when TG is >20 mmol/L, and a fasting repeat within 2 weeks for TG 10-20 mmol/L. See the NICE recommendations.
Practical interpretation
- Routine screening or statin follow-up: nonfasting is appropriate and more convenient.
- If nonfasting TG is >400 mg/dL: repeat the panel fasting.
- If TG is ≥500 mg/dL: obtain fasting confirmation promptly and evaluate secondary causes and pancreatitis risk.
- Do not rely on a Friedewald LDL-C estimate with very high TG. The classic formula becomes unacceptably inaccurate at TG >400 mg/dL, and error begins to increase above about 200 mg/dL.
Evidence update
A 2024 systematic review/meta-analysis of 244,665 participants found measurable fasting versus nonfasting variation in several lipid values and favored fasting for maximal standardization, but this does not overturn the current guideline position that nonfasting testing is adequate for most routine uses: Zaid et al., 2024, PMID: 38937752. This supports using fasting selectively when precision and triglyceride interpretation matter most.
This is a shared conversation. Sign in to Orris to start your own chat.